Loading
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Latest filing published 28 Jul 2026 for Scribe Therapeutics, Inc., €30.7M.
Filing timeline
BuySaleBehzad Aghazadeh
Insider track record
Disclosed buys
5
Disclosed sells
0
Signal history
Closed purchases
Market purchases
5
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Since each purchase
- +5.6%Entry US$18.36 · Close 19 Oct 2026 US$19.39
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Behzad Aghazadeh: trading record in brief
Behzad Aghazadeh is a declared insider at 3 companies (board member); the most frequent names are Immunomedics Inc, Scribe Therapeutics, Inc. and Whitehawk Therapeutics, Inc. Between 24 August 2017 and 28 July 2026, the trades on record add up to 14 filings.
On the market, this insider has only ever bought: 5 purchases, €43.7M in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 6 share grants. 2026 to date brings 3 purchases and no sales.
In size, the median ticket on the buying side is €1.6M. As a share of market capitalisation, the median purchase stands at 0.27%, based on 3 purchases. Of 5 purchases, 3 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The latest filing, published on 28 July 2026, reports an open-market purchase of €30.7M in Scribe Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Behzad Aghazadeh
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
2,333,333 shares@ US$15.008.55% mcap96.5% of flowCommon Stock, par value $0.0001 per shareSEC:0000902664-26-003270:0
Canonical exit: 22 Oct 2026 (T+90)
50,000 shares@ US$22.310.27% mcap3.1% of flowCommon Stock, par value $0.0001 per shareSEC:0000902664-26-003270:1
Canonical exit: 22 Oct 2026 (T+90)
7,905 shares@ US$18.250.035% mcap0.4% of flowCommon Stock, par value $0.0001 per shareSEC:0000902664-26-003270:2
Canonical exit: 26 Oct 2026 (T+90)
1,260,000 shares@ US$12.5042.9% of flowCommon Stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-22-004356:0
1,911,752 shares@ US$13.07757.1% of flowCommon Stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-21-004071:0
13,516 sharesCommon StockSEC:0001104659-20-117806:0
26,250,000 sharesCommon StockSEC:0001104659-20-117806:1
3,718 shares0Common Stock, $0.01 par value per share (''Common Stock'')SEC:0001104659-20-075724:0
100,000 shares0Common Stock, $0.01 par value per shareSEC:0001104659-20-037009:0
9,667 shares0Common Stock, $0.01 par value per share (''Common Stock'')SEC:0001104659-19-034793:0
3,849 shares0Common Stock, $0.01 par value per shareSEC:0001171843-18-006617:0
1,150,000 shares@ US$10.3986.3% of flowCommon Stock, $0.01 par value per share (the "Common Stock")SEC:0000902664-17-004365:0
Canonical exit: 12 Feb 2018 (T+90)
175,000 shares@ US$10.9713.7% of flowCommon StockSEC:0000902664-17-004365:1
Canonical exit: 13 Feb 2018 (T+90)
4,251,386 sharesCommon Stock, $0.01 par value per share (the "Common Stock")SEC:0000902664-17-003965:0
14 of 14 declarations
